Kairos Pharma Ltd (KAPA)

$0.89 -0.02 (-2.12%)
Market Cap 18.53M
Revenue (ttm) 0.00
Net Income (ttm) -2.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 161,900
Avg Vol 318,964
Day's Range N/A - N/A
Shares Out 20.82M
Stochastic %K 86%
Beta 2.20
Analysts Strong Sell
Price Target $8.33

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-948-2356
Address:
2355 Westwood Boulevard, Suite 139, Los Angeles, United States
TrdrBuckNKy
TrdrBuckNKy Dec. 5 at 12:46 PM
$KAPA I have a substantial position (for my portfolio) and I did some additional research with some help of medical assoc. in the So.Cal area...some important issues that have been propagated in various posts here were verified at a satisfactory level. I am buying some more KAPA today.
0 · Reply
stockforce123
stockforce123 Dec. 5 at 7:08 AM
$KAPA Kairos Pharma is fundamentally changing the landscape of cancer treatment for many different types of cancers. The only winning path for any giant pharma is to buy it out before Kairos Pharma becomes too BIG to buy. Any medical physician or pharmaceutical scientist knows the immeasurably huge impact ENV105 is bringing to the cancer treatment field. $KAPA will be $100 in 2026.
0 · Reply
stockforce123
stockforce123 Dec. 4 at 10:18 PM
$KAPA “Headquarters moving soon”. Confidence! J&J, Pfizer
0 · Reply
stockforce123
stockforce123 Dec. 4 at 10:12 PM
$KAPA Kairos Pharma’s ENV105 is changing the GAME of curing many different types cancers. “Striking” is a proper word to describe the huge potential and what this drug means to the world. The market need is over $50 billion between different type of cancers, over $16 billion for prostate cancer and $7 billion for lung cancer. The phase 2 results are striking.
0 · Reply
ezcheezie
ezcheezie Dec. 4 at 8:51 PM
$KAPA Another steady day on the rise. A little news to get the secret out and we're popping off.
1 · Reply
StrawberryRips
StrawberryRips Dec. 4 at 8:49 PM
$KAPA excellent bounce here
0 · Reply
stockforce123
stockforce123 Dec. 4 at 4:06 AM
$KAPA "the durability of response is striking". This is absolutely striking.
0 · Reply
Landomos
Landomos Dec. 4 at 3:37 AM
$KAPA Edging up nicely. Some great news will help move it
0 · Reply
Xtracked
Xtracked Dec. 3 at 2:57 PM
$KAPA Sooo..they need $ for Phase 3. Now they don't. News is coming
0 · Reply
Xtracked
Xtracked Dec. 3 at 2:56 PM
$KAPA I do know that a bank deal was lined up for 11/12. Twas cancelled the day before due to a ...."better deal" . All else is a mystery. My guess is a partnership offer. On average, it takes 24 business days to draw up paperwork for partnership. Two weeks yet...I hope. Completely Bullish
0 · Reply
Latest News on KAPA
Kairos Pharma Provides Shareholder Update

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Kairos Pharma Provides Shareholder Update

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 20, 2025, 8:00 AM EDT - 6 weeks ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 18, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 11, 2025, 8:00 AM EDT - 3 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 3, 2025, 8:15 AM EDT - 3 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 3 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 28, 2025, 12:28 PM EDT - 4 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 16, 2025, 8:30 AM EDT - 5 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 2:08 PM EDT - 5 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jul 15, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Jun 3, 2025, 8:15 AM EDT - 6 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 17, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Mar 20, 2025, 7:30 AM EDT - 9 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 26, 2025, 7:00 AM EST - 10 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 18, 2025, 8:30 AM EST - 10 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 11, 2025, 8:30 AM EST - 10 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Feb 6, 2025, 8:30 AM EST - 10 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 28, 2025, 8:15 AM EST - 11 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 11 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 11 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 26, 2024, 7:51 AM EST - 1 year ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma Files For U.S. IPO

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

TrdrBuckNKy
TrdrBuckNKy Dec. 5 at 12:46 PM
$KAPA I have a substantial position (for my portfolio) and I did some additional research with some help of medical assoc. in the So.Cal area...some important issues that have been propagated in various posts here were verified at a satisfactory level. I am buying some more KAPA today.
0 · Reply
stockforce123
stockforce123 Dec. 5 at 7:08 AM
$KAPA Kairos Pharma is fundamentally changing the landscape of cancer treatment for many different types of cancers. The only winning path for any giant pharma is to buy it out before Kairos Pharma becomes too BIG to buy. Any medical physician or pharmaceutical scientist knows the immeasurably huge impact ENV105 is bringing to the cancer treatment field. $KAPA will be $100 in 2026.
0 · Reply
stockforce123
stockforce123 Dec. 4 at 10:18 PM
$KAPA “Headquarters moving soon”. Confidence! J&J, Pfizer
0 · Reply
stockforce123
stockforce123 Dec. 4 at 10:12 PM
$KAPA Kairos Pharma’s ENV105 is changing the GAME of curing many different types cancers. “Striking” is a proper word to describe the huge potential and what this drug means to the world. The market need is over $50 billion between different type of cancers, over $16 billion for prostate cancer and $7 billion for lung cancer. The phase 2 results are striking.
0 · Reply
ezcheezie
ezcheezie Dec. 4 at 8:51 PM
$KAPA Another steady day on the rise. A little news to get the secret out and we're popping off.
1 · Reply
StrawberryRips
StrawberryRips Dec. 4 at 8:49 PM
$KAPA excellent bounce here
0 · Reply
stockforce123
stockforce123 Dec. 4 at 4:06 AM
$KAPA "the durability of response is striking". This is absolutely striking.
0 · Reply
Landomos
Landomos Dec. 4 at 3:37 AM
$KAPA Edging up nicely. Some great news will help move it
0 · Reply
Xtracked
Xtracked Dec. 3 at 2:57 PM
$KAPA Sooo..they need $ for Phase 3. Now they don't. News is coming
0 · Reply
Xtracked
Xtracked Dec. 3 at 2:56 PM
$KAPA I do know that a bank deal was lined up for 11/12. Twas cancelled the day before due to a ...."better deal" . All else is a mystery. My guess is a partnership offer. On average, it takes 24 business days to draw up paperwork for partnership. Two weeks yet...I hope. Completely Bullish
0 · Reply
ezcheezie
ezcheezie Dec. 3 at 1:29 PM
$KAPA LET'S GO!! 🚀🚀🚀 $8 incoming.
1 · Reply
Warrent_jr
Warrent_jr Dec. 3 at 11:59 AM
$KAPA BULLISH $15*
0 · Reply
stockforce123
stockforce123 Dec. 3 at 4:47 AM
$KAPA CEO: “Janssen, the manufacturer of apalutamide, required this step before the (phase 2) trial advanced.”
0 · Reply
Xtracked
Xtracked Dec. 3 at 3:59 AM
$KAPA Yes That is what led to our phase 1 and phase 2 trials. In the current phase 2 trial, we designed a study comparing apalutamide (a second-generation anti-androgen agent) with apalutamide plus ENV105. This is a randomized trial; however, prior to randomization, we conducted a safety lead-in with 10 patients to confirm that ENV105 is safe when combined with apalutamide. Janssen, the manufacturer of apalutamide, required this step before the trial advanced.
0 · Reply
stockforce123
stockforce123 Dec. 3 at 1:58 AM
$KAPA The CEO finally clearly said it was Jansen (Johnson & Johnson) that asked Kairos Pharma to do the phase 2 trial’s safety lead-in on ENV105 with J&J’s Apalutamide for the Prostate cancer! J&J is monitoring and working with Kairos Pharma on this trial! “Notably, several patients remain progression-free on this regimen, meaning they continue to be treatedwithout tumour growth. The median progression-free survival of 59 weeks continues to increase as these patients are followed. Although the patient number is small, the durability of response is striking.” “… which has us and some key opinion leaders in the space very excited about ENV105’s potential as a combination therapy.” J&J, Pfizer https://afurtherinquiry.substack.com/p/env105-in-advanced-prostate-cancer?utm_source=post-email-title&publication_id=675363&post_id=175131781&utm_campaign=email-post-title&isFreemail=true&r=3r4b7n&triedRedirect=true&utm_medium=email
0 · Reply
stockforce123
stockforce123 Dec. 3 at 1:46 AM
$KAPA Just published on the company’s website today:
1 · Reply
ezcheezie
ezcheezie Dec. 2 at 11:01 PM
$KAPA 👀 Let's see how tomorrow goes. Some news maybe?
0 · Reply
StrawberryRips
StrawberryRips Nov. 29 at 3:12 AM
$KAPA 🤷‍♂️
2 · Reply
joaneegell
joaneegell Nov. 29 at 1:52 AM
$KAPA so what happened today to boost this back up a little?
0 · Reply
StrawberryRips
StrawberryRips Nov. 27 at 7:57 PM
$SPY $KAPA $IXHL $LITM Happy Thanksgiving 🦃
3 · Reply
stockforce123
stockforce123 Nov. 25 at 3:16 PM
$KAPA The large pharma companies are already all over ENV105. This drug has been tested since 2018 in a phase 2 trial for prostate cancer with Pfizer’s top drug with remarkable results. Kairos Pharma took over the ownership in 2021 and has been aggressively running more extensive trials for both Lung cancer and prostate cancer. The remarkable “class effects” of the drug has been verified over and over again. The biggest pharmaceutical companies will take them over very soon.
0 · Reply
stockforce123
stockforce123 Nov. 25 at 2:39 PM
$KAPA new Linked post: “The moonshot is simple but profound: to prove that targeting resistance mechanisms can extend the effectiveness of existing drugs across cancers. If successful, this could fundamentally change how we treat cancer, transforming it into a more manageable, chronic condition and giving patients not just more time, but a better quality of life.” https://druganddeviceworld.com/2025/09/02/tackling-drug-resistance-new-frontier-in-cancer-care/
0 · Reply